Predict your next investment

Corporation
HEALTHCARE | Biotechnology
lonza.com

See what CB Insights has to offer

Investments

8

Portfolio Exits

6

Partners & Customers

10

About Lonza Group

Lonza Group (SIX: LONN) (SGX: O6Z) is a chemicals and biotechnology company. The company provides product development services to the pharmaceutical and biologic industries, including organic, fine, and performance chemicals; custom manufacturing of biopharmaceuticals; chemical synthesis capabilities; and detection systems and services for the bioscience sector.

Lonza Group Headquarter Location

Muenchensteinerstrasse 38

Basel, CH-4002,

Switzerland

+41 61 316 81 11

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Lonza Group

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Lonza Group in 3 Expert Collections, including Vitamin & Supplement Startups.

V

Vitamin & Supplement Startups

237 items

P

Pharma Startups

11,639 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

I

Infectious Disease

2,225 items

Entities aiding the surveillance, screening, prevention, diagnosis, treatment, and containment of infections & the maintenance of public wellbeing during outbreaks.

Lonza Group Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Lonza Group Rank

Research containing Lonza Group

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Lonza Group in 3 CB Insights research briefs, most recently on May 28, 2020.

Latest Lonza Group News

Food Emulsifiers Global Market Report 2021: COVID-19 Growth And Change

Oct 25, 2021

And Change" - https://www.reportlinker.com/p06177531/?utm_source=GNW V., Lonza Group Ltd., BASF SE, Puratos Group, Koninklijke DSM N.V., Beldem S.A., Lecico GmbH, Lasenor Emul, S.L., and ABITEC Corporation. The global food emulsifiers market is expected to grow from $2.76 billion in 2020 to $2.99 billion in 2021 at a compound annual growth rate (CAGR) of 8.3%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $4.07 billion in 2025 at a CAGR of 8%. The food emulsifiers market consists of sales of food emulsifier products and related services by entities (organizations, sole traders, and partnerships) which is used as surface-active agents that act as a boundary between two insoluble fluids, such as water and oil, enabling them to be blended into stable emulsions. Food emulsifiers are added in bread, salad, dressings, sauces, ice creams, puddings, and various other food items to reduce stickiness, control crystallization, and prevent separation. The main types of food emulsifiers are lecithin, monoglyceride, diglyceride, and derivatives, sorbitan ester, polyglycerol ester, and others.Lecithin is used in food applications as a lubricant, aerating agent, and viscosity transformer. The lecithin emulsifier’s molecular structure makes it a good emulsifier for the interaction of water and oil.The food emulsifiers are either natural or synthetic and are available in different forms such as fine powder, hydrate. Food emulsifiers are used in various applications such as dairy and frozen products, bakery, meat, poultry and seafood, beverage, confectionery, and others. Europe was the largest region in the food emulsifiers market in 2020.The Asia Pacific is expected to be the fastest growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. Food emulsifier manufacturers are using clear emulsion technology for safe and allergen-free emulsification of food products including beverages, nootropics, edibles, nutraceuticals, and topical.Clear emulsion technology features multiple benefits for food product developers including stability, safety, bioavailability, homogeneity, seamless integration, and others. For instance, in 2020, US-based water-soluble emulsion technology company, SORSE Technology developed SORSE Clear, a clear emulsion with a minimal sensory profile that is made with allergen-free and vegan-friendly ingredients. In December 2019, RPM International Inc., a US-based manufacturer of specialty sealants, coatings, and building materials acquired Profile Food Ingredients, LLC through its edible coatings business, Mantrose-Haeuser Co., Inc. for an undisclosed amount. Through this acquisition, Mantrose-Haeuser Co. will be able to grow its sales of specialty ingredients in the food industry and expand its international market. Profile Food Ingredients, LLC is a US-based manufacturer of dry stabilizers and emulsifier blends for the food industry. The increasing demand for packaged and convenience food across the globe is significantly contributing to the growth of the food emulsification market.Food emulsifiers are increasingly being used in packaged and convenience food products to prevent microbial spoilage. Demand for packaged and ready-to-eat food is growing due to busy lifestyles, changing eating habits of the population worldwide, and the spread of coronavirus pandemic.For instance, according to an Assocham (Associated Chamber of Commerce and Industry of India) survey conducted in 2020, roughly 79% of Indian households prefer instant food due to lack of time. Therefore, the increasing demand for packaged and ready-to-eat food is expected to drive the growth of the food emulsifiers market in the coming years. The countries covered in the food emulsifiers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Lonza Group Investments

8 Investments

Lonza Group has made 8 investments. Their latest investment was in Affinia Therapeutics as part of their Series B on May 5, 2021.

CBI Logo

Lonza Group Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

5/3/2021

Series B

Affinia Therapeutics

$110M

No

3

4/15/2020

Series A

Subscribe to see more

$99M

Subscribe to see more

10

3/27/2020

Series A

Subscribe to see more

$99M

Subscribe to see more

10

1/13/2018

Corporate Minority

Subscribe to see more

$99M

Subscribe to see more

10

12/2/2016

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/3/2021

4/15/2020

3/27/2020

1/13/2018

12/2/2016

Round

Series B

Series A

Series A

Corporate Minority

Series A

Company

Affinia Therapeutics

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$110M

$99M

$99M

$99M

$99M

New?

No

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

10

10

10

10

Lonza Group Portfolio Exits

6 Portfolio Exits

Lonza Group has 6 portfolio exits. Their latest portfolio exit was Lonza Group - Specialty Ingredients (Chemicals) on February 08, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

2/8/2021

Divestiture

$991

11

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

2/8/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Exit

Divestiture

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

11

10

10

10

10

Lonza Group Acquisitions

10 Acquisitions

Lonza Group acquired 10 companies. Their latest acquisition was Octane Biotech on October 31, 2018.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

10/31/2018

Corporate Majority

1

8/4/2017

Acq - Fin

Acquired

1

5/31/2017

Seed VC

$2.63M

Acquired

1

5/16/2017

Subscribe to see more

$99M

Subscribe to see more

10

12/15/2016

Acq - Fin

Subscribe to see more

$991

$99M

Subscribe to see more

10

Date

10/31/2018

8/4/2017

5/31/2017

5/16/2017

12/15/2016

Investment Stage

Acq - Fin

Seed VC

Acq - Fin

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

Total Funding

$2.63M

$99M

$99M

Note

Corporate Majority

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

Lonza Group Partners & Customers

10 Partners and customers

Lonza Group has 10 strategic partners and customers. Lonza Group recently partnered with Allarity Therapeutics on September 9, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

9/23/2021

Licensee

Allarity Therapeutics

Denmark

Allarity Therapeutics and Lonza Collaborate to Manufacture Dovitinib, a Renal Cell Carcinoma Candidate

Basel , Switzerland and Hoersholm , Denmark , 23 September 2021 -- Allarity Therapeutics A/S , a clinical-stage precision medicine company actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers , and Lonza Group Ltd , a CDMO partner to the biopharma industry , today announced an agreement to develop and manufacture dovitinib .

4

9/2/2021

Partner

Seppic

France

2

6/24/2021

Client

Pinteon Therapeutics

United States

Quote from Jennifer Cannon, Senior Vice President, Global Head of Mammalian Biologics, Lonza:. Pinteon Extends Collaboration with Lonza for Manufacturing PNT001, a Novel Tau Antibody Targeting Alzheimer's Disease and Traumatic Brain Injury.

Newton , USA and Basel , Switzerland , 24 June 2021 -- Pinteon Therapeutics , a biotechnology company focused on protecting neuronal health by targeting neurotoxic forms of the tau protein , and Lonza announced today that the companies have expanded their manufacturing agreement to enable future clinical production of Pinteon Therapeutics 's lead candidate , PNT001 , which showed promising results in Phase 1 clinical study .

1

6/21/2021

Client

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

6/3/2021

Licensee

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

9/23/2021

9/2/2021

6/24/2021

6/21/2021

6/3/2021

Type

Licensee

Partner

Client

Client

Licensee

Business Partner

Allarity Therapeutics

Seppic

Pinteon Therapeutics

Country

Denmark

France

United States

Subscribe to see more

Subscribe to see more

News Snippet

Allarity Therapeutics and Lonza Collaborate to Manufacture Dovitinib, a Renal Cell Carcinoma Candidate

Basel , Switzerland and Hoersholm , Denmark , 23 September 2021 -- Allarity Therapeutics A/S , a clinical-stage precision medicine company actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers , and Lonza Group Ltd , a CDMO partner to the biopharma industry , today announced an agreement to develop and manufacture dovitinib .

Quote from Jennifer Cannon, Senior Vice President, Global Head of Mammalian Biologics, Lonza:. Pinteon Extends Collaboration with Lonza for Manufacturing PNT001, a Novel Tau Antibody Targeting Alzheimer's Disease and Traumatic Brain Injury.

Newton , USA and Basel , Switzerland , 24 June 2021 -- Pinteon Therapeutics , a biotechnology company focused on protecting neuronal health by targeting neurotoxic forms of the tau protein , and Lonza announced today that the companies have expanded their manufacturing agreement to enable future clinical production of Pinteon Therapeutics 's lead candidate , PNT001 , which showed promising results in Phase 1 clinical study .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

4

2

1

10

10

Lonza Group Team

13 Team Members

Lonza Group has 13 team members, including former Chief Executive Officer, Roee Atlas.

Name

Work History

Title

Status

Roee Atlas

Chief Executive Officer

Former

Stefan Borgas

Chief Executive Officer

Former

Richard Ridinger

Chief Executive Officer

Former

Simon Sturge

Merck KGaA, Boehringer Ingelheim, OctoPlus, Vernalis, and RiboTargets

Chief Executive Officer

Former

Karen Fallen

President

Former

Name

Roee Atlas

Stefan Borgas

Richard Ridinger

Simon Sturge

Karen Fallen

Work History

Merck KGaA, Boehringer Ingelheim, OctoPlus, Vernalis, and RiboTargets

Title

Chief Executive Officer

Chief Executive Officer

Chief Executive Officer

Chief Executive Officer

President

Status

Former

Former

Former

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.